Blau Farmacêutica: Growth driven by biosimilars, mAbs, and operational efficiency boosts margins and global reach
Structural growth is fueled by patent expirations, biosimilars, and an aging population, while leadership in complex hospital drugs and a robust mAb pipeline drive expansion. Operational improvements, disciplined investments, and internationalization support strong financial performance and margin…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.